Literature DB >> 7843944

Neuroleptic malignant syndrome in an AIDS patient: clinical and pathological findings.

A S Gabellini1, A Pezzoli, P De Massis, G Casadei, A Grillo, T Sacquegna.   

Abstract

Neuroleptic malignant syndrome (NMS) has been recently described following therapy with non strictly neuroleptic drugs that alter dopaminergic function, such as sulpiride and metoclopramide, and might occur more easily in patients with functional or organic brain disorders. We observed an AIDS patient who suffered from NMS following treatment with clotiapine for insomnia and agitation. Two months later, he presented with a similar syndrome following antiemetic treatment with alizapride. On both occasions, the symptoms completely regressed after the administration of dopaminergic and muscle relaxant drugs. The patient died of pneumonia one month after the last episode. The present paper describes the clinical and pathological findings.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7843944     DOI: 10.1007/bf02339239

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  11 in total

1.  Neuroleptic malignant syndrome without rigidity.

Authors:  F Benazzi
Journal:  Ital J Neurol Sci       Date:  1991-02

2.  The (frequently) neuroleptic (potentially) malignant syndrome.

Authors:  A M Kellam
Journal:  Br J Psychiatry       Date:  1990-08       Impact factor: 9.319

3.  Severe parkinsonism in two AIDS patients taking prochlorperazine.

Authors:  H Edelstein; R T Knight
Journal:  Lancet       Date:  1987-08-08       Impact factor: 79.321

4.  Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy.

Authors:  E Hriso; T Kuhn; J C Masdeu; M Grundman
Journal:  Am J Psychiatry       Date:  1991-11       Impact factor: 18.112

5.  Neuroleptic malignant syndrome and hypothyroidism.

Authors:  A P Moore; I A Macfarlane; L D Blumhardt
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-06       Impact factor: 10.154

6.  A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal.

Authors:  J H Friedman; S S Feinberg; R G Feldman
Journal:  JAMA       Date:  1985-11-15       Impact factor: 56.272

7.  Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade?

Authors:  V W Henderson; G F Wooten
Journal:  Neurology       Date:  1981-02       Impact factor: 9.910

8.  Hypothalamic pathology in the neuroleptic malignant syndrome.

Authors:  E Horn; B Lach; Y Lapierre; P Hrdina
Journal:  Am J Psychiatry       Date:  1988-05       Impact factor: 18.112

9.  Neuroleptic malignant syndrome.

Authors:  A V Srinivasan; M Murugappan; S G Krishnamurthy; Z A Sayeed
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-06       Impact factor: 10.154

10.  Neuroleptic malignant syndrome: a case report with post-mortem brain and muscle pathology.

Authors:  E M Jones; A Dawson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-08       Impact factor: 10.154

View more
  4 in total

Review 1.  Neuroleptic malignant syndrome in the acquired immunodeficiency syndrome.

Authors:  J L Hernández; L Palacios-Araus; S Echevarría; A Herrán; J F Campo; J A Riancho
Journal:  Postgrad Med J       Date:  1997-12       Impact factor: 2.401

Review 2.  Movement disorder emergencies.

Authors:  Steven J Frucht
Journal:  Curr Neurol Neurosci Rep       Date:  2005-07       Impact factor: 5.081

Review 3.  Movement disorder emergencies.

Authors:  Kathleen L Poston; Steven J Frucht
Journal:  J Neurol       Date:  2008-08       Impact factor: 4.849

4.  Neuroleptic malignant syndrome and subsequent clozapine-withdrawal effects in a patient with refractory schizophrenia.

Authors:  Minfeng Cheng; Huaying Gu; Liangrong Zheng; Houliang Wang; Zhiyong Zhong; Shenglin Wen
Journal:  Neuropsychiatr Dis Treat       Date:  2016-03-29       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.